Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
Insmed(US:INSM) Prnewswire·2025-10-16 11:00Accessibility StatementSkip Navigation —Data on Structural Lung Changes from a High-Resolution CT Substudy to be Presented as Late-Breaker— BRINSUPRIâ"¢ (brensocatib) is a small molecule, once-daily, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age or older. Brensocatib is designed to inhibit the activation of enzymes (neutrophil serine proteases) in neutrophils that are key dr ...